Articles

Two Different Doses of Ixazomib in Patients with Relapsed MM Not Refractory to Bortezomib
ASH 2015 – Multiple Myeloma
Results of a randomized, phase 2 study to determine the confirmed overall response rate in patients treated with ixazomib, an orally bioavailable proteasome inhibitor, for patients with relapsed multiple myeloma not refractory to bortezomib. Read More ›
Ixazomib plus Lenalidomide as Maintenance Therapy Post-ASCT in Patients with MM
ASH 2015 – Multiple Myeloma
Investigators examined the safety and efficacy of the combination of lenalidomide/ixazomib as a maintenance therapy after ASCT in a single-arm phase 2 study. Favorable results of this combination may warrant additional examination in a phase 3 study. Read More ›
Pomalidomide/Dexamethasone/Ixazomib versus Pomalidomide/Dexamethasone in Patients with RRMM
ASH 2015 – Multiple Myeloma
The phase 1/2 Alliance study sought to evaluate the safety and preliminary efficacy of the combination of ixazomib/pomalidomide/dexamethasone in patients with double-refractory multiple myeloma compared with the approved combination of pomalidomide/dexamethasone. Here, they report the phase 1 portion of the Alliance study. Read More ›
Pomalidomide/Bortezomib/Low-Dose Dexamethasone in Lenalidomide-Refractory and Bortezomib-Exposed MM
ASH 2015 – Multiple Myeloma
A phase 1, multicenter study evaluated the use of PvD in patients with proteasome inhibitor–exposed and lenalidomide-refractory multiple myeloma to examine the maximum tolerated dose with secondary end points of safety, overall response rate, duration of response, and time to response. Read More ›

Page 126 of 147


© Amplity, Inc. All Rights Reserved. Privacy Policy